EP1858847A1 - Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions - Google Patents

Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions

Info

Publication number
EP1858847A1
EP1858847A1 EP06710466A EP06710466A EP1858847A1 EP 1858847 A1 EP1858847 A1 EP 1858847A1 EP 06710466 A EP06710466 A EP 06710466A EP 06710466 A EP06710466 A EP 06710466A EP 1858847 A1 EP1858847 A1 EP 1858847A1
Authority
EP
European Patent Office
Prior art keywords
donepezil hydrochloride
donepezil
stable
polymorphic
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06710466A
Other languages
German (de)
French (fr)
Inventor
Asok Nath
Mohan Prasad
Yatendra Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1858847A1 publication Critical patent/EP1858847A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention provides stable polymorphic Form I donepezil hydrochloride, processes for its preparation, use in pharmaceutical compositions and methods of treating Alzheimer's disease using the pharmaceutical compositions.
  • Donepezil is chemically, 2-[(l-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy indan- 1-one of Formula I and is used in the treatment of mild to moderate dementia of Alzheimer's type. It is commercially available as its hydrochloride salt.
  • US 4,895,841 provides a process for preparing donepezil hydrochloride by crystallizing crude donepezil hydrochloride from a mixture of methanol and diisopropyl ether. Although no particular polymorphic form is mentioned in the specification of the '841 patent, it is believed that Form I of donepezil hydrochloride is obtained by employing such crystallization.
  • US Application No 2004/0229914 provides a process for preparing crystalline Form VI of donepezil hydrochloride.
  • PCT Application WO 04/092137 provides crystalline donepezil hydrochloride Form Hl, Form H2, crystalline donepezil hydrochloride monohydrate and crystalline donepezil hydrochloride sesquihydrate.
  • US 6,734,195 provides processes for making amorphous donepezil hydrochloride.
  • PCT Patent Application WO 99/29668 provides a process for making crystal A, B and C of donepezil.
  • PCT Application WO 04/099142 provides the hydrobromide salt of donepezil. It further provides donepezil hydrobromide in solid state crystalline Forms I and II.
  • polymorphic Form I of donepezil hydrochloride when prepared as per the process reported in the prior art is not stable and has a tendency to convert to other polymorphic forms, especially Form III. It also was observed by the present inventors that after addition of ether to a solution of donepezil hydrochloride in methanol at a higher or ambient temperature, formation of Form I of donepezil is accompanied by contamination with Form III crystals if it takes more than forty five minutes to cool the resultant mass to less than 20 C. The so obtained Form I of donepezil hydrochloride, whenever stirred with water or any solvent at ambient temperature, converts to Form III at a much faster rate.
  • the present inventors have now obtained a stable polymorphic Form I donepezil hydrochloride having no or little tendency to convert to any other polymorphic form of donepezil hydrochloride.
  • a stable polymorphic Form I of donepezil hydrochloride may include one or more of the following features.
  • the donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride.
  • the donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride.
  • the donepezil hydrochloride may be incorporated into a dosage form with one or more pharmaceutically acceptable excipients.
  • the donepezil hydrochloride may have the pattern illustrated in Figures 1 and/or 2.
  • a process for preparing stable Form I of donepezil hydrochloride includes (a) adding an optionally pre-cooled anti- solvent to a solution of donepezil hydrochloride at 30°C or less; (b) rapidly cooling the resultant solution; and (c) isolating Form I of donepezil hydrochloride from the reaction mass thereof.
  • Embodiments of the process may include one or more of the following features.
  • the anti-solvent may be characterized by the donepezil hydrochloride being insoluble, practically insoluble or very slightly soluble in the anti-solvent.
  • the anti- solvent may be diisopropyl ether or diethyl ether.
  • step (b) may be cooled to 25°C or less.
  • the cooling may be effected in 30 minutes or less.
  • the donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride.
  • the donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride.
  • a pharmaceutical composition that includes stable polymorphic Form I of donepezil hydrochloride and one or more pharmaceutically acceptable excipients and diluents.
  • the donepezil hydrochloride has no tendency to convert to any other polymorphic form.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride.
  • the donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride.
  • a method of treating mild to moderate dementia of Alzheimer's type includes administering to a mammal in need thereof a therapeutically effective amount of stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form.
  • the therapeutically effective amount of donepezil hydrochloride may be in the form of a pharmaceutical composition that includes one or more pharmaceutically acceptable excipients and diluents.
  • the donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride.
  • the donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride.
  • Figure 1 is an X-Ray Powder Diffraction Pattern of stable Form I donepezil hydrochloride
  • Figure 2 is a table of the two-theta values associated with the pattern of Figure 1.
  • a first aspect of the present invention provides stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form.
  • the stable polymorphic Form I of donepezil hydrochloride of the present invention has 2% or less of other polymorphic forms of donepezil hydrochloride. More preferably the stable Form I of donepezil hydrochloride has no detectable quantity of any other known polymorphic form of donepezil hydrochloride.
  • the X-Ray powdered Diffraction (XRPD) pattern and associated two-theta values of stable Form I of donepezil hydrochloride is provided in Figures 1 and 2 of the accompanied drawing. The stability study performed on stable Form I of donepezil hydrochloride suggests that it is stable for more than 2 years under normal stability studies and for more than six months under accelerated stability studies.
  • Form I donepezil hydrochloride is stable and there is no change in the related substance content of Form I stored at 40 ⁇ 2 0 C at 75 ⁇ 5% relative humidity. There was no indication of a chemical degradation of Form I donepezil hydrochloride produced according the present invention.
  • a second aspect of the present invention provides a process for preparing stable Form I donepezil hydrochloride.
  • the process includes the steps of:
  • Donepezil hydrochloride to be used as the starting material can be prepared by any process known in the literature.
  • the so obtained donepezil hydrochloride then is dissolved in methanol by heating to reflux temperature.
  • the resultant solution can be clarified to remove foreign particulate matter or treated with activated charcoal to remove coloring and other related impurities.
  • the clear solution is cooled to a temperature of 3O 0 C or less and an optionally pre-cooled anti-solvent is added to it.
  • the anti-solvent is characterized by the fact that donepezil hydrochloride is insoluble, practically insoluble or very slightly soluble in the anti-solvent.
  • the terms insoluble, practically insoluble and very slightly soluble have their ordinary meanings as defined in United States Pharmacopoeia 2002.
  • Diisopropyl ether and diethyl ether are examples of anti-solvents that can be employed.
  • a third aspect of the present invention provides a pharmaceutical composition comprising as its active ingredient stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form.
  • the pharmaceutical composition includes one or more pharmaceutically acceptable excipients/diluents.
  • the pharmaceutical composition of the present invention may be in the form of a solid or liquid dosage forms for oral, parenteral or topical use and may have immediate or sustained release characteristics.
  • the dosage forms possible include tablets, capsules, powders, granules, creams, lotions, ointments, injectables, ophthalmic or otic solutions, suspensions, elixirs and the like.
  • a fourth aspect of the present invention provides a method of treating mild to moderate dementia of Alzheimer's type by administering to a mammal in need thereof a therapeutically effective amount of stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form.
  • the compounds described herein can be formulated into dosage forms that are suitable for administering to patients in need of the compound for treating a medical condition for which the compound is indicated, approved, or otherwise beneficial.
  • the stable Form I of donepezil hydrochloride can be formulated with one or more pharmaceutically acceptable excipients into a dosage form and administered to treat Alzheimer's type dementia.

Abstract

The present invention provides stable polymorphic Form I donepezil hydrochloride, processes for its preparation, use in pharmaceutical compositions and methods of treating Alzheimer's disease using the pharmaceutical compositions.

Description

STABLE FORM I DONEPEZIL HYDROCHLORIDE AND PROCESS FOR ITS PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS
Field of the Invention
The present invention provides stable polymorphic Form I donepezil hydrochloride, processes for its preparation, use in pharmaceutical compositions and methods of treating Alzheimer's disease using the pharmaceutical compositions.
Background of the Invention
Donepezil is chemically, 2-[(l-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy indan- 1-one of Formula I and is used in the treatment of mild to moderate dementia of Alzheimer's type. It is commercially available as its hydrochloride salt.
FORMULA I
Several processes have been reported for the preparation of donepezil or its salt (US 4,895,841; US 5,606,064; US 6,252,081; US 6,413,986; PCT Application WO 97/22584 and J. Med. Chem. 1995, 38_(24), 4821-4829). Our earlier application WO 04/086285 provides a process for preparing donepezil and its salts.
US 4,895,841 provides a process for preparing donepezil hydrochloride by crystallizing crude donepezil hydrochloride from a mixture of methanol and diisopropyl ether. Although no particular polymorphic form is mentioned in the specification of the '841 patent, it is believed that Form I of donepezil hydrochloride is obtained by employing such crystallization.
PCT Patent Application WO97/46527; WO 97/46526 and their equivalent US Patent Nos. 6,140,321 and 5,985,864 provide processes for preparing polymorphic forms I, II, III, rv and V of donepezil hydrochloride. In particular, Form I is prepared by heating donepezil hydrochloride in methanol to get a solution which is then cooled under ice cooling and to it is added diethyl ether followed by filtration of the crystals to get Form I donepezil hydrochloride. The product so obtained was found to be sticky in nature.
US Application No 2004/0229914 provides a process for preparing crystalline Form VI of donepezil hydrochloride. PCT Application WO 04/092137 provides crystalline donepezil hydrochloride Form Hl, Form H2, crystalline donepezil hydrochloride monohydrate and crystalline donepezil hydrochloride sesquihydrate. US 6,734,195 provides processes for making amorphous donepezil hydrochloride.
PCT Patent Application WO 99/29668 provides a process for making crystal A, B and C of donepezil. PCT Application WO 04/099142 provides the hydrobromide salt of donepezil. It further provides donepezil hydrobromide in solid state crystalline Forms I and II.
Summary of the Invention
The present inventors have noticed that polymorphic Form I of donepezil hydrochloride when prepared as per the process reported in the prior art is not stable and has a tendency to convert to other polymorphic forms, especially Form III. It also was observed by the present inventors that after addition of ether to a solution of donepezil hydrochloride in methanol at a higher or ambient temperature, formation of Form I of donepezil is accompanied by contamination with Form III crystals if it takes more than forty five minutes to cool the resultant mass to less than 20 C. The so obtained Form I of donepezil hydrochloride, whenever stirred with water or any solvent at ambient temperature, converts to Form III at a much faster rate.
The present inventors have now obtained a stable polymorphic Form I donepezil hydrochloride having no or little tendency to convert to any other polymorphic form of donepezil hydrochloride.
Accordingly, in one general aspect there is provided a stable polymorphic Form I of donepezil hydrochloride. Embodiments of the stable polymorphic Form I of donepezil hydrochloride may include one or more of the following features. For example, the donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride. The donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride. The donepezil hydrochloride may be incorporated into a dosage form with one or more pharmaceutically acceptable excipients. The donepezil hydrochloride may have the pattern illustrated in Figures 1 and/or 2.
In another general aspect there is provided a process for preparing stable Form I of donepezil hydrochloride. The process includes (a) adding an optionally pre-cooled anti- solvent to a solution of donepezil hydrochloride at 30°C or less; (b) rapidly cooling the resultant solution; and (c) isolating Form I of donepezil hydrochloride from the reaction mass thereof.
Embodiments of the process may include one or more of the following features. For example, the anti-solvent may be characterized by the donepezil hydrochloride being insoluble, practically insoluble or very slightly soluble in the anti-solvent. The anti- solvent may be diisopropyl ether or diethyl ether.
The solution of step (b) may be cooled to 25°C or less. The cooling may be effected in 30 minutes or less.
The donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride. The donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride.
In another general aspect there is provided a pharmaceutical composition that includes stable polymorphic Form I of donepezil hydrochloride and one or more pharmaceutically acceptable excipients and diluents. The donepezil hydrochloride has no tendency to convert to any other polymorphic form.
Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride. The donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride. In another general aspect there is provided a method of treating mild to moderate dementia of Alzheimer's type. The method includes administering to a mammal in need thereof a therapeutically effective amount of stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form.
Embodiments of the method of treating may include one or more of the following features. For example, the therapeutically effective amount of donepezil hydrochloride may be in the form of a pharmaceutical composition that includes one or more pharmaceutically acceptable excipients and diluents. The donepezil hydrochloride may have no detectable quantity of other polymorphic forms of donepezil hydrochloride. The donepezil hydrochloride may have 2% or less of other polymorphic forms of donepezil hydrochloride.
The details of one or more embodiments of the invention are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the description and claims.
Background of the Invention
Figure 1 is an X-Ray Powder Diffraction Pattern of stable Form I donepezil hydrochloride
Figure 2 is a table of the two-theta values associated with the pattern of Figure 1.
Detailed Description of the Invention
A first aspect of the present invention provides stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form. The stable polymorphic Form I of donepezil hydrochloride of the present invention has 2% or less of other polymorphic forms of donepezil hydrochloride. More preferably the stable Form I of donepezil hydrochloride has no detectable quantity of any other known polymorphic form of donepezil hydrochloride. The X-Ray powdered Diffraction (XRPD) pattern and associated two-theta values of stable Form I of donepezil hydrochloride is provided in Figures 1 and 2 of the accompanied drawing. The stability study performed on stable Form I of donepezil hydrochloride suggests that it is stable for more than 2 years under normal stability studies and for more than six months under accelerated stability studies.
It has been found that Form I donepezil hydrochloride is stable and there is no change in the related substance content of Form I stored at 40 ± 20C at 75 ± 5% relative humidity. There was no indication of a chemical degradation of Form I donepezil hydrochloride produced according the present invention.
A second aspect of the present invention provides a process for preparing stable Form I donepezil hydrochloride. The process includes the steps of:
a) adding an optionally pre-cooled anti-solvent to a solution of donepezil hydrochloride at 3O0C or less;
b) rapidly cooling the resultant solution; and
c) isolating Form I of donepezil hydrochloride from the reaction mass thereof.
Donepezil hydrochloride to be used as the starting material can be prepared by any process known in the literature. The so obtained donepezil hydrochloride then is dissolved in methanol by heating to reflux temperature. The resultant solution can be clarified to remove foreign particulate matter or treated with activated charcoal to remove coloring and other related impurities. The clear solution is cooled to a temperature of 3O0C or less and an optionally pre-cooled anti-solvent is added to it. The anti-solvent is characterized by the fact that donepezil hydrochloride is insoluble, practically insoluble or very slightly soluble in the anti-solvent. The terms insoluble, practically insoluble and very slightly soluble have their ordinary meanings as defined in United States Pharmacopoeia 2002. Diisopropyl ether and diethyl ether are examples of anti-solvents that can be employed.
After adding the anti-solvent the resultant mixture is rapidly cooled to 250C or less in less than 45 minutes and then maintained at 0 to 150C for an hour or less. The separated crystals are filtered and dried to get stable polymorphic Form I of donepezil hydrochloride. The purity of Form I of donepezil so obtained is greater than 99.9% when determined by known High Performance Liquid Chromatography (HPLC) methods. A third aspect of the present invention provides a pharmaceutical composition comprising as its active ingredient stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form. With the active ingredient, the pharmaceutical composition includes one or more pharmaceutically acceptable excipients/diluents. The pharmaceutical composition of the present invention may be in the form of a solid or liquid dosage forms for oral, parenteral or topical use and may have immediate or sustained release characteristics. The dosage forms possible include tablets, capsules, powders, granules, creams, lotions, ointments, injectables, ophthalmic or otic solutions, suspensions, elixirs and the like.
A fourth aspect of the present invention provides a method of treating mild to moderate dementia of Alzheimer's type by administering to a mammal in need thereof a therapeutically effective amount of stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLE 1
PREPARATION OF CRUDE DONEPEZIL HYDROCHLORIDE
To a stirred mixture of 2,3-dihydro-5,6-dimethoxy-2-(4-piperidinyl)methyl-indan- 1-one, hydrochloride (80 g), tetrabutyl ammonium bromide (8 g), potassium carbonate (72 g) in water (320 ml) and methylene chloride (400 ml) benzyl bromide (42.3 g) was added at ambient temperature. After addition, the reaction mixture was stirred at the same temperature. The organic layer was separated and stirred with water (160 ml) containing concentrated hydrochloric acid (51.2 ml) at ambient temperature. The organic layer was separated and concentrated under reduced pressure. The residue obtained was dissolved in water (800 ml) and extracted with ethyl acetate (400 ml). The organic layer was discarded and the pH of the aqueous layer was adjusted to 9.5 with aqueous ammonia solution. The aqueous solution then was extracted with ethyl acetate (800 ml). The ethyl acetate extract then was washed with water (2 x 600 ml). The organic layer was concentrated and the residue dissolved in methanol (480 ml). Concentrated hydrochloric acid (38.4 g) was added to the solution. Diisopropyl ether (960 ml) then was added to the solution at 250C. The solid that separated out on stirring at 5 to 1O0C was filtered and dried to get crystals of donepezil hydrochloride.
Yield: 80 g.
HPLC Purity: 99.95%.
EXAMPLE 2
PREPARATION OF STABLE POLYMORPHIC FORM I OF DONEPEZIL HYDROCHLORIDE
A mixture of crude donepezil hydrochloride (70 gm) in methanol (490 ml) was heated to reflux to get a clear solution. The solution was cooled to 250C and it diisopropyl ether (840 ml) was added to the cooled solution. The resulting mass was cooled to 1O0C in less than 15 minutes and stirred at 5-1O0C for the next 30 minutes. The separated solid was filtered and dried under reduced pressure followed by drying in air oven to get stable polymorphic Form I of donepezil hydrochloride.
Yield: 63 gm
HPLC Purity: More than 99.9%.
EXAMPLE 3
PREPARATION OF STABLE POLYMORPHIC FORM I OF DONEPEZIL HYDROCHLORIDE
A mixture of crude donepezil hydrochloride (10 gm) in methanol (70 ml) was heated to 650C to get a clear solution. The clear solution was cooled to 1O0C and diisopropyl ether (120 ml) was added to the cooled solution over 15 minutes at 5 to 1O0C. The resulting mass was stirred at 5-1O0C for the next 30 minutes. The separated solid was filtered and washed with diisopropyl ether (2 x 20 ml), and dried at 45-5O0C to get stable polymorphic Form I of donepezil hydrochloride.
Yield: 9.3 gm
HPLC Purity: More than 99.9%. EXAMPLE 4
PREPARATION OF STABLE POLYMORPHIC FORM I OF DONEPEZIL HYDROCHLORIDE
A mixture of crude donepezil hydrochloride (10 gm) in methanol (70 ml) was heated to 650C to get a clear solution. The clear solution was cooled to 2O0C and to it pre- cooled (5-1O0C) diisopropyl ether (120 ml) was added over 15 minutes at 5 to 1O0C. The resulting mass was stirred at 5-1O0C for the next 30 minutes. The separated solid was filtered and washed with diisopropyl ether (2 x 20 ml), and dried at 45-5O0C to get stable polymorphic Form I of donepezil hydrochloride.
Yield: 9.4 gm
HPLC Purity: More than 99.9%.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. For example, the compounds described herein can be formulated into dosage forms that are suitable for administering to patients in need of the compound for treating a medical condition for which the compound is indicated, approved, or otherwise beneficial. Specifically, the stable Form I of donepezil hydrochloride can be formulated with one or more pharmaceutically acceptable excipients into a dosage form and administered to treat Alzheimer's type dementia.

Claims

We Claim:
1. A stable polymorphic Form I of donepezil hydrochloride.
2. The stable polymorphic Form I of donepezil hydrochloride of claim 1, wherein the donepezil hydrochloride has no detectable quantity of other polymorphic forms of donepezil hydrochloride.
3. The stable polymorphic Form I of donepezil hydrochloride of claim 1 , wherein the donepezil hydrochloride has 2% or less of other polymorphic forms of donepezil hydrochloride.
4. The stable polymorphic Form I of donepezil hydrochloride, wherein the donepezil hydrochloride is incorporated into a dosage form with one or more pharmaceutically acceptable excipients.
5. A process for preparation of stable Form I of donepezil hydrochloride wherein the process comprises:
a) adding an optionally pre-cooled anti-solvent to a solution of donepezil hydrochloride at 3O0C or less,
b) rapidly cooling the resultant solution; and
c) isolating Form I of donepezil hydrochloride from the reaction mass thereof.
6. The process of claim 5, wherein the anti-solvent is characterized by the donepezil hydrochloride being insoluble, practically insoluble or very slightly soluble in the anti-solvent.
7. The process of claim 6, wherein the anti-solvent comprises diisopropyl ether or diethyl ether.
8. The process of claim 5, wherein the solution of step b) is cooled to 250C or less.
9. The process of claim 8, wherein the cooling is effected in 30 minutes or less.
10. The process of claim 5, wherein the donepezil hydrochloride has no detectable quantity of other polymorphic forms of donepezil hydrochloride.
11. The process of claim 5, wherein the donepezil hydrochloride has 2% or less of other polymorphic forms of donepezil hydrochloride.
12. A pharmaceutical composition comprising stable polymorphic Form I of donepezil hydrochloride and one or more pharmaceutically acceptable excipients and diluents, wherein the donepezil hydrochloride has no tendency to convert to any other polymorphic form.
13. The pharmaceutical composition of claim 12, wherein the donepezil hydrochloride has no detectable quantity of other polymorphic forms of donepezil hydrochloride.
14. The pharmaceutical composition of claim 12, wherein the donepezil hydrochloride has 2% or less of other polymorphic forms of donepezil hydrochloride.
15. A method of treating mild to moderate dementia of Alzheimer' s type, the method comprising administering to a mammal in need thereof a therapeutically effective amount of stable polymorphic Form I of donepezil hydrochloride having no tendency to convert to any other polymorphic form.
16. The method of claim 15, wherein the therapeutically effective amount of donepezil hydrochloride is in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and diluents.
17. The method of claim 15, wherein the donepezil hydrochloride has no detectable quantity of other polymorphic forms of donepezil hydrochloride.
18. The method of claim 15, wherein the donepezil hydrochloride has 2% or less of other polymorphic forms of donepezil hydrochloride.
EP06710466A 2005-02-28 2006-02-28 Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions Withdrawn EP1858847A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN436DE2005 2005-02-28
PCT/IB2006/000416 WO2006090263A1 (en) 2005-02-28 2006-02-28 Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
EP1858847A1 true EP1858847A1 (en) 2007-11-28

Family

ID=36654908

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06710466A Withdrawn EP1858847A1 (en) 2005-02-28 2006-02-28 Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions

Country Status (2)

Country Link
EP (1) EP1858847A1 (en)
WO (1) WO2006090263A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
WO2008117123A2 (en) * 2006-10-16 2008-10-02 Medichem, S.A. Process for preparing donepezil hydrochloride polymorphic form i
DE102010010998A1 (en) 2010-03-10 2011-09-15 Stada Arzneimittel Ag A solid pharmaceutical composition comprising donepezil hydrochloride of crystalline polymorphic form I
CN103694164B (en) * 2014-01-23 2015-08-12 天津大学 A kind of New crystal form of donepezil hydrochloride and preparation method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1053576A (en) * 1996-06-07 1998-02-24 Eisai Co Ltd Polymorphic crystal of donepezil hydrochloride and its production
AU731282B2 (en) * 1996-06-07 2001-03-29 Eisai Co. Ltd. Polymorphs of donepezil hydrochloride and process for production
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical compositions containing donepezil hydrocholoride
US20070129549A1 (en) * 2003-03-21 2007-06-07 Yatendra Kumar Stable lamotrigine pharmaceutical compositions and processes for their preparation
US7560560B2 (en) * 2003-04-16 2009-07-14 Hetero Drugs Limited Crystalline forms of donepezil hydrochloride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006090263A1 *

Also Published As

Publication number Publication date
WO2006090263A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
NO171453B (en) PROCEDURE FOR THE PREPARATION OF CRYSTALLINIC PAROXETIN HYDROCHLORIDE-HEMI HYDRATE
EP0579681B1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
SK167698A3 (en) Polymorphs of donepezil hydrochloride and process for production
CN1505614A (en) Process for making amlodipine maleate
US7592459B2 (en) Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
EP3243824A1 (en) Solid forms of ibrutinib free base
JP2015508090A (en) Solid form dabigatran etexilate mesylate and process for its preparation
US20030191347A1 (en) Venlafaxine base
CA2433366C (en) Amlodipine free base
US6706710B2 (en) Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
WO2006090263A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
CA2164296C (en) Heterocyclic chemistry
JP3864991B2 (en) Crystals of (±) 2- (dimethylamino) -1-{[O- (m-methoxyphenethyl) phenoxy] methyl} ethyl hydrogen succinate hydrochloride
US7335380B2 (en) Amlodipine free base
JP2006160766A (en) CRYSTAL OF (±)2-(DIMETHYLAMINO)-1-{[O-(m-METHOXYPHENETHYL)PHENOXY]METHYL}ETHYL HYDROGEN SUCCINATE HYDROCHLORIDE
JP2006160764A (en) CRYSTAL OF (±)2-(DIMETHYLAMINO)-1-{[O-(m-METHOXYPHENETHYL)PHENOXY]METHYL}ETHYL HYDROGEN SUCCINATE HYDROCHLORIDE
MXPA01012328A (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2. 2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists.
EP2072510A1 (en) Crystalline form of azelastine
JP2010077155A (en) CRYSTAL OF (±)2-(DIMETHYLAMINO)-1-{[O-(m-METHOXYPHENETYL)PHENOXY]METHYL}ETHYL HYDROGEN SUCCINATE HYDROCHLORIDE
EP1355632B1 (en) Amlodipine free base
WO2002060441A1 (en) Novel forms of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo (1,2-a)pyridine-6-carboxamide
JPH09176119A (en) Crystal of piperidine derivative, its production intermediate and production process
KR20060034636A (en) Sibutramine free base in crystalline form and its pharmaceutical use
WO2006051340A1 (en) Novel form of celecoxib
KR20100101405A (en) Method of preparing non-crystalline (+)-lansoprazole and (+)-lansoprazole alcoholate used therein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20071217

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080429